Solanezumab
Solanezumab is a pharmaceutical drug with 9 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
4
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
4 of 8 finished
50.0%
4 ended early
1
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Clinical Trials (9)
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9